Last edition
News about
Defence Therapeutics Advances Precision Radiopharmaceutical Development with CNL
Defence Therapeutics Inc., a publicly traded biotechnology company focused on precision intracellular drug delivery, has announced an expansion of its long-standing collaboration with Canadian Nuclear Laboratories (CNL) to accelerate the development of its radiopharmaceutical pipeline.
NanoMosaic Secures FDA AMT Designation for Nanoneedle Technology in AAV Gene Therapy Manufacturing
FDA’s CBER grants Advanced Manufacturing Technology designation to NanoMosaic’s Nanoneedle platform, enhancing regulatory engagement and streamlining quality control in AAV gene therapy production.
Grail Submits Final PMA Module to FDA for Galleri Multi-Cancer Early Detection Test
Grail files the final Premarket Approval module with the FDA for its Breakthrough Device-designated Galleri test, supported by data from over 25,000 participants in PATHFINDER 2 and the NHS-Galleri trial.
Avobis Bio to Present Expanded STOMP2 Trial Data on AVB-114 at ECCO Congress
Expanded STOMP2 trial data highlight sustained safety and efficacy of AVB-114, as Avobis Bio prepares for Phase III development in Crohn’s disease.
SK Bioscience Begins Study of Sarbecovirus Vaccine
SK bioscience has initiated a global phase I/II clinical trial of GBP511, a universal vaccine candidate targeting the Sarbecovirus family, leveraging its SKYCovione recombinant protein platform and nanoparticle technology as part of the company’s mid- to long-term strategy to advance next-generation vaccines for future pandemic preparedness.
Concerto and Sacco System Sign Microbial Discovery Deal
Concerto and Sacco System aim to develop novel ingredients composed of synergistically interacting microbes with desirable functional properties.
Alvotech Reaches Global Settlement on Eylea Biosimilar
The settlement enables Alvotech and its partners to launch the biosimilar from January 1, 2026 in the UK and Canada, from May 1, 2026 in the EEA and other markets outside the US, and in Japan from May 2026 for select indications, expanding to all approved indications from November 1, 2026.
Lilly Bets Big on Precision Immunology in USD 1.93 Billion Partnership
Eli Lilly and Company has entered into a strategic collaboration with biotechnology firm Repertoire Immune Medicines in a deal valued at up to USD 1.93 billion to develop novel therapies for autoimmune diseases.
AstraZeneca Commits USD 15 Billion to Expand Manufacturing and R&D in China
UK-based pharmaceutical major AstraZeneca has announced a USD 15 billion investment in China by 2030, marking its largest-ever commitment to the country. The investment is aimed at expanding the company’s research, development and manufacturing capabilities, reinforcing China’s role as a key pillar in AstraZeneca’s global growth strategy.
Evestia Clinical Expands European Footprint with Acquisition of ICRC-Weyer
Evestia Clinical, a global independent specialist contract research organization (CRO), has announced the acquisition of Berlin-based ICRC-Weyer GmbH, a long-established CRO and scientific consultancy with strong expertise in data-driven clinical research.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy